Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Assets (2023 - 2025)

Xenetic Biosciences' Assets history spans 6 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, Assets rose 21.19% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $8.4 million, up 21.19%, while the annual FY2025 figure was $8.4 million, 21.19% up from the prior year.
  • Assets reached $8.4 million in Q4 2025 per XBIO's latest filing, up from $5.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $13.7 million in Q1 2023 to a low of $5.1 million in Q3 2025.
  • Average Assets over 3 years is $8.9 million, with a median of $8.7 million recorded in 2024.
  • The largest YoY upside for Assets was 21.19% in 2025 against a maximum downside of 40.73% in 2025.
  • A 3-year view of Assets shows it stood at $10.6 million in 2023, then tumbled by 34.92% to $6.9 million in 2024, then increased by 21.19% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Assets are $8.4 million (Q4 2025), $5.1 million (Q3 2025), and $5.4 million (Q2 2025).